|
Levine, Jon David |
University Of California, San Francisco |
Chronic Chemotherapy Peripheral Neuropathy: Role of Neuroplasticity and Stress |
|
|
Im, Eun-Ok |
Emory University |
Cancer Pain Management: A Technology-Based Intervention for Asian American Breast Cancer Survivors |
RFA-NS-22-037: HEAL Initiative: Advancing Health Equity in Pain and Comorbidities |
|
Brinkman, Tara M |
St. Jude Children'S Research Hospital |
Culturally adapted mobile treatment of chronic pain in adolescent survivors of pediatric bone sarcoma |
RFA-NS-22-037: HEAL Initiative: Advancing Health Equity in Pain and Comorbidities |
|
Cheville, Andrea Lynne |
Mayo Clinic Rochester |
Achieving Equity through SocioCulturally-informed, Digitally-Enabled Cancer Pain managemeNTā (ASCENT) Clinical Trial |
RFA-NS-22-002: HEAL Initiative: Advancing Health Equity in Pain Management |
|
Wang, Jing |
New York University School Of Medicine |
Optimizing the use of ketamine to reduce chronic postsurgical pain |
RFA-NS-20-028: HEAL Initiative: Pain Management Effectiveness Research Network: Clinical Trial Planning and Implementation Cooperative Agreement (UG3/UH3 Clinical Trial Required) |
|
Melemedjian, Ohannes Kevork |
University Of Maryland Baltimore |
Identification of novel targets for the treatment of chemotherapy-induced painful peripheral neuropathy |
RFA-NS-18-043: Discovery and Validation of Novel Targets for Safe and Effective Pain Treatment |
|
Shen, Chan |
Pennsylvania State Univ Hershey Med Ctr |
The effects of hydrocodone rescheduling on pain management of older lung cancer patients |
RFA-DE-22-011: HEAL Initiative: Secondary Analysis and Integration of Existing Data Related to Acute and Chronic Pain Development or Management in Humans |
|
Laack, Nadia N |
Mayo Clinic Rochester |
Utility of memantine in preventing cognitive dysfunction in children receiving cranial radiotherapy |
RFA-CA-19-033: Improving Outcomes for Pediatric, Adolescent and Young Adult Cancer Survivors |
|
Hu, Shuiying |
Ohio State University |
Prevention of paclitaxel-induced peripheral neuropathy with nilotinib |
RFA-CA-18-019: Research Answers to National Cancer Institute's (NCI) Provocative Questions |
|
Tighiouart, Mourad |
Cedars-Sinai Medical Center |
Advancing Analysis and Interpretation ofAdverse Events and PROs in Cancer Clinical Trials |
RFA-CA-17-052: Analyzing and Interpreting Clinician and Patient Adverse Event Data to Better Understand Tolerability |
|
Basch, Ethan M. |
Univ Of North Carolina Chapel Hill |
Analyzing and Interpreting PRO-CTCAE with CTCAE and Other Clinical Data to Characterize Drug Tolerability |
RFA-CA-17-052: Analyzing and Interpreting Clinician and Patient Adverse Event Data to Better Understand Tolerability |
|
Gray, Robert J |
Dana-Farber Cancer Inst |
Analysis of ECOG-ACRIN adverse event data to optimize strategies for the longitudinal assessment of tolerability in the context of evolving cancer treatment paradigms (EVOLV) |
RFA-CA-17-052: Analyzing and Interpreting Clinician and Patient Adverse Event Data to Better Understand Tolerability |
|
Mohile, Supriya G |
University Of Rochester |
Understanding Treatment Tolerability in Older Patients with Cancer |
RFA-CA-17-052: Analyzing and Interpreting Clinician and Patient Adverse Event Data to Better Understand Tolerability |
|
Grace, Peter |
University Of Tx Md Anderson Can Ctr |
PQ12 Targeting HDAC6 for Chemotherapy-Induced Neuropathy and Chemobrain |
RFA-CA-17-017: Research Answers to NCI's Provocative Questions |
|
Prigerson, Holly Gwen |
Weill Medical Coll Of Cornell Univ |
Behavioral and Psychosocial Effects on Study Outcomes in End-Stage Cancer Treatment (BEST End-Stage Cancer Study) |
PAR-21-333: NCI Outstanding Investigator Award |
